Louis Belzie, MD
Psychiatry · Brooklyn, NYNPI 1861438681
Payments from drug & device makers
Across 959 payments — averaging $167.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$64K
- Teva Pharmaceuticals USA, Inc.$41K
- E.r. Squibb & Sons, L.L.C.$21K
- Avanir Pharmaceuticals, Inc.$10K
- Sunovion Pharmaceuticals Inc.$6K
- Neurocrine Biosciences, Inc.$4K
- plus $15K from 27 others
What the payments were for
- Consulting fees$14,3759%
- Speaking & faculty fees$109,92668%
- Travel & lodging$6,7624%
- Food & beverage$29,32218%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 133 | $63,973 |
| Teva Pharmaceuticals USA, Inc. | 121 | $40,677 |
| E.r. Squibb & Sons, L.L.C. | 30 | $21,114 |
| Avanir Pharmaceuticals, Inc. | 15 | $9,575 |
| Sunovion Pharmaceuticals Inc. | 72 | $5,997 |
| Neurocrine Biosciences, Inc. | 99 | $4,494 |
| Otsuka America Pharmaceutical, Inc. | 138 | $3,756 |
| Alkermes, Inc. | 102 | $3,251 |
| AbbVie(2 entities) | 97 | $2,157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $2,038 |
| Vanda Pharmaceuticals Inc. | 45 | $1,003 |
| Lundbeck LLC | 27 | $558 |
| Indivior Inc. | 8 | $272 |
| Almatica Pharma LLC | 11 | $268 |
| Bioxcel Therapeutics, Inc. | 7 | $154 |
| Luye Pharma (USA) Ltd. | 1 | $130 |
| Axsome Therapeutics, Inc. | 2 | $127 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
| Gilead | 1 | $119 |
| Merck | 6 | $118 |
| Ivantis, Inc | 1 | $105 |
| Biogen | 4 | $81 |
| Smith+Nephew | 2 | $48 |
| Brainsway USA Inc | 2 | $46 |
| Noven Therapeutics, LLC | 2 | $42 |
| Janssen Scientific Affairs, LLC | 1 | $38 |
| Corium, LLC | 1 | $25 |
| UCB, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| EMD Serono, Inc. | 1 | $16 |
| Theratechnologies Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$61,559
- INVEGA TRINZA$57,950
- AUSTEDO$24,586
- Austedo XR$13,796
- NUEDEXTA$9,325
- COBENFY$5,274
- LATUDA$4,486
- INGREZZA$2,450
- ARISTADA$2,420
- LYBALVI$2,380
- CAPLYTA$1,604
- ARISTADA INITIO$605
- REXULTI$383
- UZEDY$364
- ABILIFY MAINTENA$349
- SPRAVATO$251
- VRAYLAR$250
- ERZOFRI EXTENDED-RELEASE$130
- PERSERIS$125
- VOQUEZNA$125
How this compares
$160,504 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 19 | $99,229 |
| Invega SustennaPaliperidone Palmitate | 15 | $36,332 |
| Abilify MaintenaAripiprazole | 13 | $34,600 |
| RexultiBrexpiprazole | 20 | $29,171 |
| VraylarCariprazine Hcl | 18 | $24,521 |
| NamzaricMemantine Hcl/Donepezil Hcl | 26 | $15,673 |
| Lurasidone Hcl | 28 | $5,970 |
| Memantine Hcl ErMemantine Hcl | 11 | $1,523 |
| Clonazepam | 190 | $1,246 |
| Donepezil Hcl | 190 | $1,016 |
| Haloperidol | 39 | $770 |
| Escitalopram Oxalate | 112 | $747 |
| Risperidone | 131 | $730 |
| Zolpidem Tartrate | 147 | $725 |
| Sertraline Hcl | 128 | $707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $40,677 | $99,22919 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $3,756 | $63,77133 claims |
| AbbVieVraylar, Namzaric | $2,157 | $40,19444 claims |
| Johnson & JohnsonInvega Sustenna | $63,973 | $36,33215 claims |
| Almatica Pharma LLCSertraline Hcl | $268 | $707128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Brooklyn
- Inna Yuryev-GolgerBrooklyn$3M
- Zinoviy BenzarBrooklyn$505K
- Nikhil PalekarBrooklyn$481K
- Mark OwensBrooklyn$286K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.